At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 39 enrolled
Drug / intervention
Nivolumabdrug
Likely dose
Nivolumab 480 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single Arm Phase 2 Study of Adjuvant Nivolumab After Salvage Resection in Head and Neck Squamous Cell Carcinoma Patients Previously Treated With Definitive Therapy
In Brief
A Phase 2 clinical trial evaluating Nivolumab for Head and Neck Cancer. Completed, enrolled 39 participants across 2 sites.
Detailed Summary
The purpose of this research study is to test the safety and efficacy of nivolumab after salvage resection in head and neck cancer in patients that have previously received definitive radiation with or without chemotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHead and Neck Cancer
CountriesUnited States
CollaboratorsBristol-Myers Squibb
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedNov 2017
Enrollment StartDec 2017
Primary CompletionJan 2024
Study CompletionApr 2026
TodayJul 2026
First PostedNov 28, 2017
Enrollment StartDec 6, 2017
Primary CompletionJan 1, 2024
Study CompletionApr 15, 2026
TodayJul 2, 2026
Enrollment to primary: 6.1 yearsPosted 8.6 years ago
Interventions
Nivolumabdrug
Nivolumab 480 mg IV infusion